Archive for 2018

  • aside

    First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

    GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

    by
  • First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

    GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

    by
  • aside

    Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

    GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of…

    by
  • Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

    GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of…

    by
  • aside

    Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of…

    by
  • Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of…

    by
  • aside

    Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

    GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the…

    by
  • Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

    GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the…

    by
  • aside

    Isofol presents a poster at ESMO 2018 Congress in Germany

    Isofol is attending the ESMO 2018 Congress in Germany, which is taking place between October 19-23. During Sunday the poster, “ISO-CC-005;…

    by
  • aside

    New Chairman and extended board at Isofol Medical AB (publ)

    Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday…

    by